Novo Nordisk A/S vs Boston Beer Company Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Boston Beer Company Inc trades at $170.75 (market cap $1.88B). The key difference: Novo Nordisk A/S is far larger — about 117.3× Boston Beer Company Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| NVO | SAM | |
|---|---|---|
Market Cap | $220.53B | $1.88B |
Sector | Health | Consumer Staples |
52-Week High | $71.70 | $260.05 |
52-Week Low | $35.29 | $161.08 |
Enterprise Value | $239.49B | $1.75B |
Dividend Yield | 3.63% | — |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →